All stocks today
71229 stocks real-time data.
All stocks today

Stock quotes

Stock market live

Historical stock prices

Stocks market capitalization

Dividend stocks

Stock earnings

Stock revenue

Stock ratings. Where to invest?

Jounce Therapeutics, Inc. revenue reports

Jounce Therapeutics, Inc. financial reports, Jounce Therapeutics, Inc. annual revenue in 2024. When does Jounce Therapeutics, Inc. report revenue?
Add to widgets
Added to widgets

Jounce Therapeutics, Inc. total revenue, net income and dynamics of changes in US dollar today

Net revenue of Jounce Therapeutics, Inc. on 31/03/2021 amounted to 1 539 000 $. Net income of Jounce Therapeutics, Inc. today amounted to -26 535 000 $. Net income, revenue and dynamics - the main financial indicators of Jounce Therapeutics, Inc.. The financial report schedule from 30/06/2018 to 31/03/2021 is available online. The value of "net income" Jounce Therapeutics, Inc. on the graph is displayed in blue. The value of all Jounce Therapeutics, Inc. assets on the graph is shown in green.

Report date Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
and Change (%)
Comparing current quartal report this year to quartal report last year.
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
and Change (%)
Comparing current quartal report this year to quartal report last year.
31/03/2021 1 539 000 $ -85.985 % ↓ -26 535 000 $ -
31/12/2020 62 339 000 $ +210.14 % ↑ 35 472 000 $ -
30/09/2020 0 $ -100 % ↓ -24 903 000 $ -
30/06/2020 0 $ -100 % ↓ -27 968 000 $ -
31/03/2019 10 981 000 $ - -12 377 000 $ -
31/12/2018 20 100 000 $ - -2 040 000 $ -
30/09/2018 14 528 000 $ - -7 637 000 $ -
30/06/2018 19 378 000 $ - -4 674 000 $ -
Show:
to

Jounce Therapeutics, Inc. financial report charts

The latest dates of Jounce Therapeutics, Inc. financial statements available online: 30/06/2018, 31/12/2020, 31/03/2021. The dates of the financial statements are determined by the accounting rules. The latest date of the financial report of Jounce Therapeutics, Inc. is 31/03/2021. Gross profit Jounce Therapeutics, Inc. is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services. Gross profit Jounce Therapeutics, Inc. is -7 762 000 $

Jounce Therapeutics, Inc. quarterly report dates

Cost of revenue Jounce Therapeutics, Inc. is the total cost of producing and distributing of products and services of a company. Cost of revenue Jounce Therapeutics, Inc. is 9 301 000 $ Total revenue Jounce Therapeutics, Inc. refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods. Total revenue Jounce Therapeutics, Inc. is 1 539 000 $ Operating income Jounce Therapeutics, Inc. is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS). Operating income Jounce Therapeutics, Inc. is -26 583 000 $

Net income Jounce Therapeutics, Inc. is an entity's income minus cost of goods sold, expenses and taxes for an accounting period. Net income Jounce Therapeutics, Inc. is -26 535 000 $ Current assets Jounce Therapeutics, Inc. is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year. Current assets Jounce Therapeutics, Inc. is 267 013 000 $ Total assets Jounce Therapeutics, Inc. refers to the total amount of assets owned by a person or entity. Total assets Jounce Therapeutics, Inc. is 305 153 000 $

31/03/2021 31/12/2020 30/09/2020 30/06/2020 31/03/2019 31/12/2018 30/09/2018 30/06/2018
Gross profit
Gross profit is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services.
-7 762 000 $ 55 538 000 $ -8 989 000 $ -21 023 000 $ 4 294 000 $ 12 896 000 $ 7 572 000 $ 10 698 000 $
Cost of revenue
Cost of revenue is the total cost of producing and distributing of products and services of a company.
9 301 000 $ 6 801 000 $ 8 989 000 $ 21 023 000 $ 6 687 000 $ 7 204 000 $ 6 956 000 $ 8 680 000 $
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
1 539 000 $ 62 339 000 $ - - 10 981 000 $ 20 100 000 $ 14 528 000 $ 19 378 000 $
Operating revenue
Operating revenue is revenue generated from a company's primary business activities. For example, a retailer produces revenue through merchandise sales, and a physician derives revenue from the medical services he/she provides.
- - - - 10 981 000 $ 20 100 000 $ 14 528 000 $ 19 378 000 $
Operating income
Operating income is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS).
-26 583 000 $ 35 421 000 $ -25 104 000 $ -28 249 000 $ -13 491 000 $ -3 145 000 $ -8 740 000 $ -5 640 000 $
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
-26 535 000 $ 35 472 000 $ -24 903 000 $ -27 968 000 $ -12 377 000 $ -2 040 000 $ -7 637 000 $ -4 674 000 $
R&D spending
Research and Development spending - cost of investigative activities to improve existing products and procedures or to lead to the development of new products and procedures.
9 829 000 $ 7 696 000 $ 9 013 000 $ 9 013 000 $ 9 158 000 $ 7 984 000 $ 8 338 000 $ 8 382 000 $
Operating expense
An operating expense is an expenditure that a business incurs as a result of performing its normal business operations.
28 122 000 $ 26 918 000 $ 25 104 000 $ 28 249 000 $ 24 472 000 $ 23 245 000 $ 23 268 000 $ 25 018 000 $
Current assets
Current assets is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year.
267 013 000 $ 211 391 000 $ 107 457 000 $ 131 311 000 $ 169 884 000 $ 192 209 000 $ 214 365 000 $ 235 330 000 $
Total assets
Total assets refers to the total amount of assets owned by a person or entity.
305 153 000 $ 244 236 000 $ 135 833 000 $ 158 901 000 $ 213 209 000 $ 214 452 000 $ 234 236 000 $ 253 155 000 $
Current cash
Current cash - the sum of all of the cash a company has on the date of report.
196 273 000 $ 147 493 000 $ 67 103 000 $ 74 463 000 $ 40 172 000 $ 47 906 000 $ 53 283 000 $ 50 109 000 $
Current debt
Current debt is the portion of debt due within a year (12 months) and is listed as a current liability and part of net working capital.
- - - - 75 719 000 $ 65 546 000 $ 69 754 000 $ 65 681 000 $
Total cash
Total cash - the sum of all of the cash a company has on its books, including petty cash and funds on deposit in a bank.
- - - - - - - -
Total debt
Total debt is a combination of both short-term and long-term debt. Short-term debts are those that must be paid back within a year. Long-term debt generally includes every liability that must be paid off in more than a year.
- - - - 118 785 000 $ 110 323 000 $ 130 826 000 $ 144 660 000 $
Debt ratio
Total debt to total assets - is a financial ratio that indicates the percentage of a company's assets that are provided via debt.
- - - - 55.71 % 51.44 % 55.85 % 57.14 %
Shareholders equity
Shareholder's equity (SE) is the owner's claim after subtracting total liabilities from total assets.
279 454 000 $ 211 294 000 $ 105 087 000 $ 127 269 000 $ 94 424 000 $ 104 129 000 $ 103 410 000 $ 108 495 000 $
Cash flow
Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business.
- - - - -23 183 000 $ -19 438 000 $ -18 498 000 $ -4 558 000 $

Last revenue report of Jounce Therapeutics, Inc. was 31/03/2021. According to last financial report total revenue in Jounce Therapeutics, Inc. was 1 539 000 US dollar and changed by -85.985% since last year. Net income in Jounce Therapeutics, Inc. was -26 535 000 $ in last quartal, net income changes to 0%.

Current cash Jounce Therapeutics, Inc. - the sum of all of the cash a company has on the date of report. Current cash Jounce Therapeutics, Inc. is 196 273 000 $

Jounce Therapeutics, Inc. stocks data

Jounce Therapeutics, Inc. financials